Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
2(20%)
Results Posted
67%(4 trials)
Terminated
2(20%)

Phase Distribution

Ph phase_1
6
60%
Ph phase_2
4
40%

Phase Distribution

6

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
6(60.0%)
Phase 2Efficacy & side effects
4(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

10

all time

Status Distribution
Active(2)
Completed(6)
Terminated(2)

Detailed Status

Completed6
Terminated2
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
2
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 16 (60.0%)
Phase 24 (40.0%)

Trials by Status

active_not_recruiting110%
terminated220%
recruiting110%
completed660%

Recent Activity

2 active trials
Showing 5 of 10
completedphase_1

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

NCT02073123
recruitingphase_1

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

NCT05106296
active_not_recruitingphase_2

Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG

NCT04049669
completedphase_1

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

NCT02052648
terminatedphase_2

A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma

NCT03301636
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT02073123Phase 1

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

Completed
NCT05106296Phase 1

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Recruiting
NCT04049669Phase 2

Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG

Active Not Recruiting
NCT02052648Phase 1

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Completed
NCT03301636Phase 2

A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma

Terminated
NCT02460367Phase 1

Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer

Terminated
NCT02502708Phase 1

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Completed
NCT01792050Phase 2

Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer

Completed
NCT02077881Phase 1

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Completed
NCT01560923Phase 2

Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10